Etifoxine

	WikiDoc Resources for Etifoxine
Articles
Most recent articles on Etifoxine Most cited articles on Etifoxine Review articles on Etifoxine Articles on Etifoxine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Etifoxine Images of Etifoxine Photos of Etifoxine Podcasts & MP3s on Etifoxine Videos on Etifoxine
Evidence Based Medicine
Cochrane Collaboration on Etifoxine Bandolier on Etifoxine TRIP on Etifoxine
Clinical Trials
Ongoing Trials on Etifoxine at Clinical Trials.gov Trial results on Etifoxine Clinical Trials on Etifoxine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Etifoxine NICE Guidance on Etifoxine NHS PRODIGY Guidance FDA on Etifoxine CDC on Etifoxine
Books
Books on Etifoxine
News
Etifoxine in the news Be alerted to news on Etifoxine News trends on Etifoxine
Commentary
Blogs on Etifoxine
Definitions
Definitions of Etifoxine
Patient Resources / Community
Patient resources on Etifoxine Discussion groups on Etifoxine Patient Handouts on Etifoxine Directions to Hospitals Treating Etifoxine Risk calculators and risk factors for Etifoxine
Healthcare Provider Resources
Symptoms of Etifoxine Causes & Risk Factors for Etifoxine Diagnostic studies for Etifoxine Treatment of Etifoxine
Continuing Medical Education (CME)
CME Programs on Etifoxine
International
Etifoxine en Espanol Etifoxine en Francais
Business
Etifoxine in the Marketplace Patents on Etifoxine
Experimental / Informatics
List of terms related to Etifoxine

Etifoxine
Clinical data
ATC code	N05BX03 (WHO) ;
Identifiers
	IUPAC name 6-chloro-N-ethyl-4-methyl-4-phenyl- 4H-benzo[d][1,3]oxazin-2-amine;
CAS Number	21715-46-8;
PubChem CID	30768;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C17H17ClN2O
Molar mass	300.782 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Etifoxine (or etafenoxine) is an anxiolytic and anticonvulsant drug.^[1] It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.^[2] It is more effective than lorazepam as an anxiolytic, but has less side effects.^[3]

Unlike benzodiazepines, etifoxine appears to produce its anxiolytic effects by binding to β2 and β3 subunits of the GABA_A receptor complex, and so is acting at a different target site to benzodiazepines, although the physiological effect that is produced is similar to that of benzodiazepines.^[4] This difference in binding means that etifoxine can be used alongside benzodiazepines to potentiate their effects without competing for binding sites,^[5] however it also means that the effects of etifoxine are not reversed by the benzodiazepine antagonist flumazenil.^[6]

Template:Pharmacology-stub

References

↑ Kruse HJ, Kuch H. Etifoxine: evaluation of its anticonvulsant profile in mice in comparison with sodium valproate, phenytoin and clobazam. Arzneimittelforschung. 1985;35(1):133-5.
↑ Schlichter R, Rybalchenko V, Poisbeau P, Verleye M, Gillardin J. Modulation of GABAergic synaptic transmission by the non-benzodiazepine anxiolytic etifoxine. Neuropharmacology. 2000 Jul 10;39(9):1523-35.
↑ Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Le Guern ME, Micallef J, Blin O. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Human Psychopharmacology. 2006 Apr;21(3):139-49.
↑ Hamon A, Morel A, Hue B, Verleye M, Gillardin JM. The modulatory effects of the anxiolytic etifoxine on GABA(A) receptors are mediated by the beta subunit. Neuropharmacology. 2003 Sep;45(3):293-303.
↑ Kruse HJ, Kuch H. Potentiation of clobazam's anticonvulsant activity by etifoxine, a non-benzodiazepine tranquilizer, in mice. Comparison studies with sodium valproate. Arzneimittelforschung. 1986 Sep;36(9):1320-2.
↑ Verleye M, Schlichter R, Gillardin JM. Interactions of etifoxine with the chloride channel coupled to the GABA(A) receptor complex. Neuroreport. 1999 Oct 19;10(15):3207-10.

The Merck Index, 12th Edition. 3910

Template:Anxiolytics

[1] Kruse HJ, Kuch H. Etifoxine: evaluation of its anticonvulsant profile in mice in comparison with sodium valproate, phenytoin and clobazam. Arzneimittelforschung. 1985;35(1):133-5.

[2] Schlichter R, Rybalchenko V, Poisbeau P, Verleye M, Gillardin J. Modulation of GABAergic synaptic transmission by the non-benzodiazepine anxiolytic etifoxine. Neuropharmacology. 2000 Jul 10;39(9):1523-35.

[3] Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Le Guern ME, Micallef J, Blin O. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Human Psychopharmacology. 2006 Apr;21(3):139-49.

[4] Hamon A, Morel A, Hue B, Verleye M, Gillardin JM. The modulatory effects of the anxiolytic etifoxine on GABA(A) receptors are mediated by the beta subunit. Neuropharmacology. 2003 Sep;45(3):293-303.

[5] Kruse HJ, Kuch H. Potentiation of clobazam's anticonvulsant activity by etifoxine, a non-benzodiazepine tranquilizer, in mice. Comparison studies with sodium valproate. Arzneimittelforschung. 1986 Sep;36(9):1320-2.

[6] Verleye M, Schlichter R, Gillardin JM. Interactions of etifoxine with the chloride channel coupled to the GABA(A) receptor complex. Neuroreport. 1999 Oct 19;10(15):3207-10.

[1]

[2]

[3]

[4]

[5]

[6]

Clinical data

ATC code	N05BX03 (WHO)
Identifiers
IUPAC name 6-chloro-N-ethyl-4-methyl-4-phenyl- 4H-benzo[d][1,3]oxazin-2-amine
CAS Number	21715-46-8
PubChem CID	30768
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₇H₁₇ClN₂O
Molar mass	300.782 g/mol

Etifoxine

Overview

References

Navigation menu

Search